» Articles » PMID: 29732377

Risk Factors for Community-Associated Infection in Adults: A Case-Control Study

Abstract

Background: An increasing proportion of infections (CDI) in the United States are community-associated (CA). We conducted a case-control study to identify CA-CDI risk factors.

Methods: We enrolled participants from 10 US sites during October 2014-March 2015. Case patients were defined as persons age ≥18 years with a positive specimen collected as an outpatient or within 3 days of hospitalization who had no admission to a health care facility in the prior 12 weeks and no prior CDI diagnosis. Each case patient was matched to one control (persons without CDI). Participants were interviewed about relevant exposures; multivariate conditional logistic regression was performed.

Results: Of 226 pairs, 70.4% were female and 52.2% were ≥60 years old. More case patients than controls had prior outpatient health care (82.1% vs 57.9%; < .0001) and antibiotic (62.2% vs 10.3%; < .0001) exposures. In multivariate analysis, antibiotic exposure-that is, cephalosporin (adjusted matched odds ratio [AmOR], 19.02; 95% CI, 1.13-321.39), clindamycin (AmOR, 35.31; 95% CI, 4.01-311.14), fluoroquinolone (AmOR, 30.71; 95% CI, 2.77-340.05) and beta-lactam and/or beta-lactamase inhibitor combination (AmOR, 9.87; 95% CI, 2.76-340.05),-emergency department visit (AmOR, 17.37; 95% CI, 1.99-151.22), white race (AmOR 7.67; 95% CI, 2.34-25.20), cardiac disease (AmOR, 4.87; 95% CI, 1.20-19.80), chronic kidney disease (AmOR, 12.12; 95% CI, 1.24-118.89), and inflammatory bowel disease (AmOR, 5.13; 95% CI, 1.27-20.79) were associated with CA-CDI.

Conclusions: Antibiotics remain an important risk factor for CA-CDI, underscoring the importance of appropriate outpatient prescribing. Emergency departments might be an environmental source of CDI; further investigation of their contribution to CDI transmission is needed.

Citing Articles

Costs and Outcomes of Clostridioides difficile Infections in Germany: A Retrospective Health Claims Data Analysis.

Schley K, Heinrich K, Moisi J, Hackl D, Obermuller D, Brestrich G Infect Dis Ther. 2024; 14(1):91-104.

PMID: 39565511 PMC: 11782737. DOI: 10.1007/s40121-024-01075-1.


A call to action: the SHEA research agenda to combat healthcare-associated infections.

Kwon J, Advani S, Branch-Elliman W, Braun B, Cheng V, Chiotos K Infect Control Hosp Epidemiol. 2024; 1-18.

PMID: 39448369 PMC: 11518679. DOI: 10.1017/ice.2024.125.


Bacterial metabolites influence the autofluorescence of .

Ticer T, Tingler A, Glover J, Dooley S, Kendrick J, Zackular J Front Microbiol. 2024; 15:1459795.

PMID: 39439940 PMC: 11493716. DOI: 10.3389/fmicb.2024.1459795.


Informing estimates of probability of infection for testing and treatment: expert consensus from a modified-Delphi procedure.

Baghdadi J, Wessel M, Dubberke E, Lydecker A, Claeys K, Alonso C Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e168.

PMID: 39411667 PMC: 11474763. DOI: 10.1017/ash.2024.387.


Beyond Antibiotics: Novel Approaches in the Treatment of Recurrent Infection.

Zaidi S, Haider R, Kazmi S, Husnain A, Khan S, Merchant S ACG Case Rep J. 2024; 11(8):e01333.

PMID: 39081300 PMC: 11286250. DOI: 10.14309/crj.0000000000001333.


References
1.
Wilcox M, Mooney L, Bendall R, Settle C, Fawley W . A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008; 62(2):388-96. DOI: 10.1093/jac/dkn163. View

2.
Weber D, Rutala W . The role of the environment in transmission of Clostridium difficile infection in healthcare facilities. Infect Control Hosp Epidemiol. 2011; 32(3):207-9. DOI: 10.1086/658670. View

3.
Kundrapu S, Sunkesula V, Jury L, Cadnum J, Nerandzic M, Musuuza J . Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?. BMC Infect Dis. 2016; 16:159. PMC: 4835867. DOI: 10.1186/s12879-016-1514-2. View

4.
Jury L, Sitzlar B, Kundrapu S, Cadnum J, Summers K, Muganda C . Outpatient healthcare settings and transmission of Clostridium difficile. PLoS One. 2013; 8(7):e70175. PMC: 3722238. DOI: 10.1371/journal.pone.0070175. View

5.
Wiuff C, Brown D, Mather H, Banks A, Eastaway A, Coia J . The epidemiology of Clostridium difficile in Scotland. J Infect. 2011; 62(4):271-9. DOI: 10.1016/j.jinf.2011.01.015. View